A Phase 4 interventional study of Tadalafil and Placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 40 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-04.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 8th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2010, is one of 26 in phase 4, and was the 28th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 623 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 7th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 22nd registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Partner Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
Drug: Tadalafil
5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
Drug: Tadalafil
for 12 weeks
Drug: Placebo
Administer orally
Also known as: Cialis, LY450190
Administer orally
Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period)
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of double-blind treatment period (Period III).
Time frame: Baseline through 12 weeks
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score
Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score
Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12-Week in Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 1-5
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Patient
The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint
The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.
Time frame: Week 12
Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence)
Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12-Week Endpoint in Treatment Satisfaction Scale (TSS) - Partner
The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
Time frame: Baseline, 12 weeks
Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint
The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.
Time frame: Week 12
Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of open-label extension treatment period (Period IV).
Time frame: 12 weeks through 16 weeks
Change From 12 Weeks to 16 Weeks in Participant's International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.
Time frame: 12 weeks and 16 weeks
Change From Week 12 to Week 16 Percentage of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 3
Assessed the percentage of Yes responses to the SEP diary Question 3 "Did your erection last long enough for you to have successful intercourse?" from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).
Time frame: 12 weeks and 16 weeks
| Milestone | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | 5 mg Tadalafil Open-Label Extension |
|---|---|---|---|---|
| Started | 207 | 207 | 209 | 0 |
| Received at least 1 dose of study drug | 205 | 205 | 207 | 0 |
| Completed | 186 | 189 | 190 | 0 |
| Not completed | 21 | 18 | 19 | 0 |
| Withdrew: Adverse event | 3 | 3 | 2 | 0 |
| Withdrew: Entry criteria not met | 4 | 2 | 4 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 3 | 4 | 2 | 0 |
| Withdrew: Withdrawal by subject | 7 | 7 | 6 | 0 |
| Milestone | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | 5 mg Tadalafil Open-Label Extension |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 562 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 546 |
| Completed | 0 | 0 | 0 | 552 |
| Not completed | 0 | 0 | 0 | 10 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of double-blind treatment period (Period III).
| percentage of participants | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week Endpoint (Double-Blind Treatment Period) | 38.7 | 39.6 | 12.1 |
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score | 7.9 ± 0.49 | 8.1 ± 0.49 | 1.8 ± 0.49 |
Self-reported intercourse satisfaction over the past 4 weeks. IIEF-IS is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Intercourse Satisfaction (IIEF-IS) Domain Score | 2.8 ± 0.21 | 2.6 ± 0.21 | 0.6 ± 0.21 |
Self-reported overall satisfaction over the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14; each question scored as 1 (low/no satisfaction) through 5 (high satisfaction) with total subscore for the 2 questions of 2 to 10. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function - Overall Satisfaction (IIEF-OS) Domain Score | 2.4 ± 0.16 | 2.4 ± 0.16 | 0.6 ± 0.16 |
Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Questions 1-5. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| percentage of "yes" responses | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Question 1: Able to Achieve Erection | 12.2 ± 1.63 | 11.4 ± 1.62 | 1.8 ± 1.62 |
| Question 2: Able to Insert | 26.2 ± 2.25 | 26.1 ± 2.23 | 6.9 ± 2.23 |
| Question 3: Successful Intercourse | 37.3 ± 2.52 | 39.4 ± 2.50 | 12.6 ± 2.51 |
| Question 4: Satisfied with Hardness | 44.2 ± 2.73 | 42.8 ± 2.70 | 11.5 ± 2.71 |
| Question 5: Overall Satisfaction with Experience | 43.6 ± 2.70 | 41.2 ± 2.68 | 10.6 ± 2.68 |
The TSS measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Confidence to complete sexual activity | 27.0 ± 1.78 | 29.2 ± 1.78 | 3.8 ± 1.77 |
| Ease of erection | 24.0 ± 1.69 | 24.7 ± 1.69 | 4.1 ± 1.68 |
| Pleasure from sexual activity | 22.6 ± 1.58 | 22.7 ± 1.58 | 3.3 ± 1.57 |
| Erectile function satisfaction | 31.0 ± 1.82 | 33.6 ± 1.81 | 4.9 ± 1.81 |
| Satisfaction with orgasm | 25.6 ± 1.90 | 26.3 ± 1.89 | 6.2 ± 1.88 |
The TSS - patient satisfaction with medication measured participant satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Treatment Satisfaction Scale (TSS) - Patient Satisfaction With Medication Score at Week 12 Endpoint | 53.7 ± 1.98 | 55.9 ± 1.98 | 24.8 ± 1.97 |
Self-reported erectile function over the past 4 weeks. Question 15, confidence in the ability to get an erection, is scored from 1 (very low confidence) to 5 (very high confidence). Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Change From Baseline to 12-Week Endpoint in the International Index of Erectile Function (IIEF) Question 15 (Sexual Confidence) | 1.2 ± 0.08 | 1.3 ± 0.08 | 0.3 ± 0.08 |
The TSS measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score for each of five TSS domains (confidence to complete sexual activity, ease of erection, pleasure from sexual activity, erectile function satisfaction, and satisfaction with orgasm) was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Least Squares (LS) mean of the change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model included centered-baseline as a covariate and factors of study, treatment group, and pooled site within study, and centered-baseline-by-treatment-group interaction.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Confidence to complete sexual activity | 23.7 ± 2.01 | 27.2 ± 1.99 | 2.0 ± 1.99 |
| Ease of erection | 23.1 ± 1.76 | 25.3 ± 1.75 | 0.7 ± 1.75 |
| Pleasure from sexual activity | 18.2 ± 1.69 | 18.5 ± 1.68 | 1.3 ± 1.68 |
| Erectile function satisfaction | 28.6 ± 1.84 | 28.5 ± 1.83 | 3.4 ± 1.83 |
| Satisfaction with orgasm | 18.7 ± 2.06 | 21.0 ± 2.05 | 3.6 ± 2.04 |
The TSS - partner satisfaction with medication measured participant's partner satisfaction with treatment based on a 13-item questionnaire. The overall score was converted to a 0-100 scale with higher numbers on the scale indicating greater satisfaction. Satisfaction with medication was analyzed using analysis of covariance (ANOVA). The model included factors of study, treatment group, and pooled site within study.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period III) | 5 mg Tadalafil (Period III) | Placebo (Period III) |
|---|---|---|---|
| Treatment Satisfaction Scale (TSS) - Partner Satisfaction With Medication Score at Week 12 Endpoint | 52.5 ± 1.97 | 55.7 ± 1.96 | 27.5 ± 1.96 |
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants who return to normal erectile function (IIEF-EF domain score ≥26) at end of open-label extension treatment period (Period IV).
| percentage of participants | 2.5 mg Titrated to 5 mg Tadalafil (Period IV) | 5 mg Tadalafil (Period IV) | Placebo (Period IV) |
|---|---|---|---|
| Percentage of Participants Having International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 From 12 to 16 Weeks | 54.5 | 59.8 | 62.8 |
Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function.
| units on a scale | 2.5 mg Titrated to 5 mg Tadalafil (Period IV) | 5 mg Tadalafil (Period IV) | Placebo (Period IV) |
|---|---|---|---|
| End of Week 12 | 22.4 ± 6.71 | 22.5 ± 7.07 | 16.0 ± 7.39 |
| End of Week 16 | 24.1 ± 6.44 | 24.2 ± 6.46 | 24.4 ± 6.73 |
Assessed the percentage of Yes responses to the SEP diary Question 3 "Did your erection last long enough for you to have successful intercourse?" from Week 12 (end of double-Blind treatment) to Week 16 (end of open-label treatment).
| percentage of "yes" responses | 2.5 mg Titrated to 5 mg Tadalafil (Period IV) | 5 mg Tadalafil (Period IV) | Placebo (Period IV) |
|---|---|---|---|
| End of Week 12 | 68.3 ± 38.25 | 69.0 ± 37.88 | 43.1 ± 39.03 |
| End of Week 16 | 75.0 ± 34.49 | 75.5 ± 34.89 | 80.0 ± 34.37 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2.5 mg Titrated to 5 mg Tadalafil | — | 1/205 (0.5%) | 46/205 (22.4%) |
| 5 mg Tadalafil | — | 1/205 (0.5%) | 68/205 (33.2%) |
| Placebo | — | 1/207 (0.5%) | 50/207 (24.2%) |
| 5 mg Tadalafil Open-Label Extension | — | 3/546 (0.5%) | 23/546 (4.2%) |
| Event | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | 5 mg Tadalafil Open-Label Extension |
|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/205 | 1/205 | 0/207 | 0/546 |
| Chest discomfortGeneral disorders | 1/205 | 0/205 | 0/207 | 0/546 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 1/205 | 0/205 | 0/207 | 0/546 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/205 | 0/205 | 1/207 | 0/546 |
| Cholecystitis acuteHepatobiliary disorders | 0/205 | 0/205 | 0/207 | 1/546 |
| Meningitis viralInfections and infestations | 0/205 | 0/205 | 0/207 | 1/546 |
| SyncopeNervous system disorders | 0/205 | 0/205 | 0/207 | 1/546 |
| Event | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | 5 mg Tadalafil Open-Label Extension |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/205 | 9/205 | 7/207 | 4/546 |
| DyspepsiaGastrointestinal disorders | 2/205 | 6/205 | 1/207 | 0/546 |
| Back painMusculoskeletal and connective tissue disorders | 3/205 | 6/205 | 1/207 | 2/546 |
| DiarrhoeaGastrointestinal disorders | 2/205 | 3/205 | 3/207 | 0/546 |
| BronchitisInfections and infestations | 3/205 | 2/205 | 0/207 | 0/546 |
| NasopharyngitisInfections and infestations | 2/205 | 3/205 | 1/207 | 0/546 |
| SinusitisInfections and infestations | 1/205 | 3/205 | 1/207 | 2/546 |
| Upper respiratory tract infectionInfections and infestations | 3/205 | 2/205 | 3/207 | 0/546 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/205 | 3/205 | 0/207 | 0/546 |
| DizzinessNervous system disorders | 1/205 | 3/205 | 1/207 | 1/546 |
| Age Continuous(years) | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | Total |
|---|---|---|---|---|
| Mean | 57.3 ± 10.68 | 58.1 ± 10.36 | 57.6 ± 10.17 | 57.6 ± 10.39 |
| Sex: Female, Male(Participants) | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 207 | 207 | 209 | 623 |
| Ethnicity (NIH/OMB)(Participants) | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 10 | 9 | 27 |
| Not Hispanic or Latino | 199 | 197 | 200 | 596 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 2 | 2 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 29 | 24 | 35 | 88 |
| White | 173 | 177 | 167 | 517 |
| More than one race | 3 | 1 | 2 | 6 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | 2.5 mg Titrated to 5 mg Tadalafil | 5 mg Tadalafil | Placebo | Total |
|---|---|---|---|---|
| United States | 199 | 195 | 191 | 585 |
| Canada | 8 | 11 | 18 | 37 |
| Puerto Rico | 0 | 1 | 0 | 1 |
The record gives a start of Aug 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil